- Grants since 2016
- 145
- Awarded, last 5 years (where amounts are published)
- $500k
- Funded works, last 5 years
- 1 228
- Funded works, all time
- 2 889
Grants
2018–2022 · research · SU2C CONVERGENCE™ RESEARCH TEAM
Connecting Immune Health and Tumor Biology in Gynecologic Cancers
E. John Wherry · Memorial Sloan Kettering Cancer Center
2018 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2018)
CUPID-SEQ-HIGH THROUGHPUT TRANSCRIPTOMIC SPATIAL MAPPING OF IMMUNE-TUMOR INTERACTIONS IN THE MICROENVIRONMENT
Dan Landau
2018–2019 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM GENENTECH
Immunotherapy Combination Strategies in ER-Positive Metastatic Breast Cancer
Ingrid A. Mayer · University of California, San Francisco
2018–2022 · research · SU2C–LUSTGARTEN FOUNDATION PANCREATIC CANCER INTERCEPTION RESEARCH TEAM
Developing Novel Approaches to Detect and Treat Early Pancreatic Cancer
David P. Ryan · Johns Hopkins University
2018–2025 · research · PANCREATIC CANCER COLLECTIVE RESEARCH TEAM — NEW THERAPIES CHALLENGE
Exploiting DNA Repair Gene Mutations in Pancreatic Cancer
Alan D. D’Andrea · Dana-Farber Cancer Institute
2018–2020 · research · PANCREATIC CANCER COLLECTIVE RESEARCH TEAM–NEW THERAPIES CHALLENGE
Targeting Stem Cell Signals in Pancreatic Cancer
Tannishtha Reya · University of California, San Francisco
2018–2022 · research · SU2C CONVERGENCE™ RESEARCH TEAM
Single-Cell Functional Multi-omics to Characterize and Monitor CAR T Therapy
Rong Fan · University of Pennsylvania
2018–2022 · research · SU2C MULTIPLE MYELOMA DREAM TEAM
Screening and Interception of Precursor Myeloma
Irene M. Ghobrial · Mayo Clinic
2018 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2018)
INTERROGATING IMPACT OF EPIGENETIC MODIFIERS ON DURABLE REPROGRAMMING OF EXHAUSTED CD8 T CELLS IN PATIENTS WITH NSCLC TREATED WITH PD-1 BLOCKADE
E. John Wherry
2018–2021 · research · SU2C CONVERGENCE™ RESEARCH TEAM
Responders and Non-Responders to Endometrial Cancers With Mismatch Repair
Alessandro D. Santin · University of California San Diego
2018–2026 · research · PANCREATIC CANCER COLLECTIVE RESEARCH TEAM — NEW THERAPIES CHALLENGE
Molecularly Targeted Radionuclide Therapy via the Integrin αvß6
Julie L. Sutcliffe · University of California, Davis
2018–2024 · research · SU2C – LUSTGARTEN FOUNDATION PANCREATIC CANCER INTERCEPTION DREAM TEAM
Intercepting Pancreatic Cancer in High-Risk Cohorts
Anirban Maitra · University of California San Diego
2018–2027 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM GENENTECH
Neoadjuvant Therapy for Patients With High-Risk Stage III Melanoma
Matthew S. Block · University of Minnesota
2018 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2018)
STUDIES OF COLORECTAL CANCER PATIENT– DERIVED ORGANOIDS TO VALIDATE CANDIDATE BIOMARKERS OF RESISTANCE TO NATURAL KILLER CELLS
Michal Sheffer
2018–2024 · research · PANCREATIC CANCER COLLECTIVE RESEARCH TEAM—NEW THERAPIES CHALLENGE
Immunotherapy Targeting Mutant KRAS
Robert H. Vonderheide · University of Pennsylvania
2017–2021 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM GENENTECH
Overcoming Urothelial Cancer Atezolizumab Resistance by Epigenetic Therapy
Peter A. Jones · USC Norris Comprehensive Cancer Center
2017–2021 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM BRISTOL MYERS SQUIBB
Immunotherapy to Prevent Progression in Multiple Myeloma
Irene M. Ghobrial · Weill Cornell Medicine
2017 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2017)
PROBING THE METABOLIC INTERACTIONS BETWEEN TUMOR AND STROMA IN PANCREATIC CANCER
Matthew G. Vander Heiden
2017 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2017)
APTAMER-BASED DETECTION AND BINDING OF PEPTIDE-MHC COMPLEXES
Cassian Yee
2017–2020 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM BRISTOL MYERS SQUIBB
Tumor Infiltrating Lymphocyte Adoptive T-Cell Therapy for Non-small Cell Lung Cancer (NSCLC)
Eric B. Haura · University of Florida
2017–2024 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM MERCK
Pembrolizumab and Radiation Therapy to Improve Outcome in High-Risk Sarcoma
David G. Kirsch · Weill Cornell Medicine
2017–2024 · research · SU2C COLORECTAL CANCER DREAM TEAM
Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer
Luis A. Diaz · Massachusetts General Hospital
2017 · research · SU2C Innovative Research Grant (Class of 2017)
REPROGRAMMING TUMOR IMMUNOGENICITY WITH STING-ACTIVATING NANOPARTICLES
John T. Wilson · Vanderbilt University
2017 · research · SU2C Innovative Research Grant (Class of 2017)
IDENTIFYING AND TARGETING MECHANISMS OF RESISTANCE TO IMMUNOTHERAPY
Rizwan Haq · Dana-Farber Cancer Institute
2017–2022 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM BRISTOL MYERS SQUIBB
Reversing Primary Anti-PD-1 Resistance with Ipilimumab and Nivolumab
Antoni Ribas · Huntsman Cancer Institute
2017 · research · SU2C Innovative Research Grant (Class of 2017)
TARGETING THE PRO-METASTATIC NICHE IN THE LIVER FOR CANCER IMMUNOTHERAPY
Gregory L. Beatty · University of Pennsylvania
2017–2022 · research · ST. BALDRICK’S FOUNDATION–SU2C PEDIATRIC CANCER DREAM TEAM
Immunogenomics to Create New Therapies for High-Risk Childhood Cancers
John M. Maris · University of Pittsburgh
2017–2019 · research · SU2C–LUNGEVITY FOUNDATION–AMERICAN LUNG ASSOCIATION LUNG CANCER INTERCEPTION RESEARCH TEAM
Blood-Based Early Interception of Lung Cancer
Lecia V. Sequist · Stanford University
2017 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2017)
INTERROGATION OF RESISTANCE MECHANISMS TO CHECKPOINT INHIBITORS USING FUNCTIONAL GENOMICS
Siwen Hu-Lieskovan
2017 · research · SU2C Innovative Research Grant (Class of 2017)
REWORKING NEGATIVE RECEPTOR SIGNALS FOR IMPROVED ANTI-GLIOMA T-CELL THERAPY
Meenakshi G. Hegde · Baylor College of Medicine
2017–2022 · research · SU2C–LUSTGARTEN FOUNDATION TRANSLATIONAL RESEARCH TEAM
Chimeric Antigen Receptor T-cell (CAR T) Therapy for Pancreatic Cancer
Carl H. June · University of Pennsylvania
2017 · research · SU2C Innovative Research Grant (Class of 2017)
HARNESSING DIPEPTIDYL PEPTIDASE INHIBITION FOR CANCER IMMUNOTHERAPY
Daniel A. Bachovchin · Memorial Sloan Kettering Cancer Center
2017–2022 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM MERCK
Combined Epigenetic Therapy and Pembrolizumab for Advanced Non-small Cell Lung Cancer (NSCLC)
Stephen B. Baylin · Johns Hopkins University
2017 · research · SU2C Innovative Research Grant (Class of 2017)
POTENTIATING NOVEL ENGINEERED CELLULAR THERAPIES FOR SOLID TUMORS
Marcela V. Maus · Massachusetts General Hospital
2017–2020 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM MERCK
Targeting VDR to Make Pancreatic Cancer Competent for Immunotherapy
Daniel D. Von Hoff · University of California San Diego
2017 · research · SU2C Innovative Research Grant (Class of 2017)
T-CELL IMMUNOTHERAPY FOR CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA
Marie E. Bleakley · Fred Hutch Cancer Center
2017 · research · SU2C Innovative Research Grant (Class of 2017)
RESCUING T-CELL FUNCTION FOR IMMUNOTHERAPY OF PEDIATRIC MALIGNANCIES
David M. Barrett · Children's Hospital of Philadelphia
2017 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2017)
DISSECTING THE EPIGENETIC MECHANISMS OF REPEAT RNA REGULATION IN CANCER
David T. Ting
2017 · research · SU2C Innovative Research Grant (Class of 2017)
IMAGING CAR T CELLS WITH A DUAL- FUNCTION PET REPORTER GENE
Michael D. Farwell · University of Pennsylvania
2017–2022 · research · SU2C–LUSTGARTEN FOUNDATION TRANSLATIONAL RESEARCH TEAM
Chimeric Antigen Receptor T-cell (CAR T) Therapy for Pancreatic Cancer
Carl H. June · University of Pennsylvania